



January 28, 2015

## **Zafgen Announces Closing of Public Offering of Common Stock and Full-Exercise of Option to Purchase Additional Shares**

BOSTON, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) today announced the closing of its underwritten public offering of 3,942,200 shares of its common stock at a price of \$35.00 per share before underwriting discounts, which includes the full-exercise of the underwriters' option to purchase an additional 514,200 shares of common stock at the public offering price, less the underwriting discounts.

Leerink Partners LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Canaccord Genuity Inc. and JMP Securities LLC acted as co-managers.

A registration statement relating to this offering was declared effective by the U.S. Securities and Exchange Commission on January 22, 2015. Copies of the prospectus for this offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 6142, or by email at [Syndicate@leerink.com](mailto:Syndicate@leerink.com); or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by phone (631) 274-2806 / Fax (631) 254-7140.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

### **About Zafgen**

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.

### **Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for Zafgen, Inc., including statements about Zafgen's public offering, future expectations, plans and prospects for the company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials, expectations of expanding ongoing clinical trials and other factors discussed in the "Risk Factors" section of Zafgen's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, which is on file with the Securities and Exchange Commission (SEC), the "Risk Factors" section of Zafgen's Registration Statement on Form S-1 related to this public offering, and in other filings that Zafgen may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Zafgen expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations Contact:

Shauna Elkin

(212) 850-5613

[Shauna.Elkin@fticonsulting.com](mailto:Shauna.Elkin@fticonsulting.com)